Russ Cohen

Insightful Insider Trades: A Closer Look at Recent Stocks Movement Insightful Insider Trades: A Closer Look at Recent Stocks Movement

$21M Bet On Comstock Resources? Check Out These 3 Stocks Insiders Are Buying

Although the U.S. stocks closed higher last Friday, there were notable insider trades worth examining.

Insiders buying shares might suggest confidence in the company’s future or belief in the stock’s value. It can offer insight but should not be the sole basis for investment decisions.

Let’s delve into some recent notable insider purchases and see what they reveal about the companies. For a more extensive list, refer to Benzinga’s insider transactions platform.

ZoomInfo Technologies

  • The Trade: The CEO of ZoomInfo Technologies Inc. bought 1,500,000 shares at an average price of $8.49, totaling approximately $12.7 million.
  • What’s Happening: ZoomInfo reported underwhelming financial results for the second quarter and announced a management transition on August 5.
  • What ZoomInfo Technologies Does: ZoomInfo Technologies Inc. offers a go-to-market intelligence platform catering to sales and marketing teams.

Groupon

  • The Trade: Director Jason Harinstein acquired 15,000 shares of Groupon, Inc. at an average price of $10.61, with a total cost of about $159,150.
  • What’s Happening: Groupon recorded a loss for the second quarter on July 30.
  • What Groupon Does: Groupon Inc. acts as a mediator between consumers and merchants, offering various products and services at discounts through its online platform.

Disney

  • The Trade: Director Calvin McDonald purchased 11,756 shares of The Walt Disney Company at an average price of $85.06, costing around $999,994.
  • What’s Happening: Walt Disney reported positive quarterly earnings on August 7.
  • What Disney Does: Disney operates across three global business sectors: entertainment, sports, and experiences, with its franchises and characters playing a pivotal role in its success over the decades.
See also  SciSparc Licenses SCI-160 Pain Drug Program to Polyrizon Exploration of SciSparc's Strategic Move Towards Pain Treatment